Aim: In this multicentre study, we aimed to compare hepatic and tumour related outcomes of local regional Forskolin mw therapy for HCC in patients with chronic HBV or HCV with and without the MetS. Method: Patients with viral hepatitis treated with local regional therapy (transarterial chemoembolisation +/- radiofrequency ablation) for HCC between 2007-2013 in two large Sydney hospitals were included in this retrospective study. Medical records for these patients were audited for patient demographics, hepatic and tumour characteristics at diagnosis, number and intervals of local regional therapy

as well as episodes of hepatic decompensation (jaundice, ascites, varices, encephalopathy, infections). Patients with viral hepatitis were classified into 2 groups according to the presence Kinase Inhibitor Library manufacturer of absence of the MetS, as defined by the Adult Treatment Panel III. Results: A total of 69 patients were included in the study, 32 patients with the MetS and 37 patients without. The mean age of the whole group was 60.9 ± 12.1 and the male to female ratio was 4.31. Demographics and clinical data of patients with and without the MetS are presented in table 1. With respect to tumour response outcomes, there was no statistical difference in the average number of local regional therapy sessions in both groups (2.3±1.62 vs 2.1 ±1.53, p=0.5373), and the intervals between therapies. In contrast,

with respect to hepatic decompensations; significantly more episodes of hepatic decompensation were seen in those with MetS than those without MetS (34% vs 11%, p=0.0220). Conclusion: In patients either with HCC and viral hepatitis treated with local regional therapy, presence of metabolic syndrome is associated with significantly higher rates of hepatic

decompensation. Disclosures: Jacob George – Advisory Committees or Review Panels: Roche, BMS, MSD, Gilead, Janssen The following people have nothing to disclose: Fei Wen Chen, Amany Zekry HCC is still an unsolved burden with a rising incidence worldwide. Hypoxia and HIF1-alpha expression is a known negative predictor for overall survival. HIF1-alpha is mainly expressed in highly aggressive hcc. Cut homeobox 1 (CUX1) gene is a target of loss-of-heterozygoticy in many cancers, yet elevated CUX1 expression is frequently observed and is associated with shorter disease-free survival. It plays a critical role in the RAS dependent DNA repair under oxidative stress. The role of CUX1 in hcc is still uninvestigated. In the present study the influence of HIF-1-alpha on CUX1 expression in vitro and its effect on apoptosis and proliferation were investigated. HIF-1-alpha was induced in HepG-2-cells by Cobald chloride (CoCl). CUX1 was downregulated by 3 different si RNA. Markers of apoptosis and apoptosis like bax/bcl-2 were determined by westernblotting, RT-PCR and imunohistochemistery.